MAR 10, 2022 8:00 AM PST

Drug Equipped with Iron Sensor Halts Cancer Tumor Growth

WRITTEN BY: Annie Lennon

A modified version of an FDA-approved drug can halt tumor growth driven by mutations in the RAS gene, which are notoriously difficult to treat and account for around a quarter of cancer-related deaths. The corresponding study was published in the Journal of Experimental Medicine by researchers at the University of California, San Francisco. 

Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive and least-survivable cancers, with a 5-year survival rate of under 9%. Mutations in the RAS gene are a key feature of this cancer and are known to drive uncontrolled proliferation and survival of cancer cells. 

Currently, anticancer drug, cobimetinib, is used to treat this kind of cancer. While it blocks excessive growth activity in cancer cells, it also blocks growth in other, non–cancerous cells leading to side effects patients find difficult to handle. 

Previous studies indicate that many tumors driven by the KRAS form of RAS mutations have elevated concentrations of highly reactive ferrous iron, and that amounts of this kind of iron correlate with shorter survival times. 

With this in mind, the researchers modified cobimetinib with a small, molecular sensor for ferrous iron that only ‘turns the drug on’ when in contact with ferrous iron in cancer cells. 

The researchers first tested the new drug on normal tissues such as skin. These tests showed it was able to prevent adverse effects of regular cobimetinib, and so the researchers proceeded to test the new drug in mouse models of KRAS-driven cancers. From these experiments, they found that the drug worked just as effectively as cobimetinib in shrinking tumors but with reduced toxicity with regard to other cells. 

The researchers then used the new drug in combination with other synergistic anticancer drugs. They once again found that it was better at inhibiting tumor growth and better tolerated than similar combinations with cobimetinib. 

The researchers say that by removing toxicity from cobimetinib, they can now explore ten new combination treatments for KRAS-driven cancers. They are also in the midst of conducting work to see if a similar approach may be applied to antibiotics.

"I love taking care of patients, and a fundamental part of that is, ultimately, getting a molecule to the place where it's needed and keeping it out of places where it's not needed," said Eric Collisson, MD, a senior author of the study and member of the UCSF Helen Diller Family Comprehensive Cancer Center. 

"To be able to deliver a therapy that's five times more potent than what we currently have and not run the patient ragged, that's pretty exciting,” he concluded. 

 

Sources: Science DailyJournal of Experimental Medicine

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 21, 2022
Clinical & Molecular DX
An Emerging Need to Diagnose Maladaptive Daydreaming
APR 21, 2022
An Emerging Need to Diagnose Maladaptive Daydreaming
Maladaptive daydreaming (MD), also called daydreaming disorder, occurs in people who experience intense daydreams o ...
APR 26, 2022
Immunology
Unraveling the Mystery of an Immune Cell Checkpoint
APR 26, 2022
Unraveling the Mystery of an Immune Cell Checkpoint
The immune system can get tired when it has to fight against a chronic infection or a disease like cancer. Exhausted T c ...
JUN 07, 2022
Health & Medicine
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
JUN 07, 2022
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
JUN 17, 2022
Cannabis Sciences
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
JUN 17, 2022
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
A study published in the scientific journal Addiction found that people will be more likely to use cannabis as their sta ...
JUL 01, 2022
Drug Discovery & Development
Paper-thin Device Treats Pain and then Dissolves in Body
JUL 01, 2022
Paper-thin Device Treats Pain and then Dissolves in Body
Researchers have developed a biocompatible, implantable device that relieves pain and harmlessly dissolves when no longe ...
Loading Comments...